Skip to main content
Equibles
SMMT logo

SMMT · Summit Therapeutics Inc. · Analyst Estimates

Track SMMT — free

Use SMMT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SMMT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$15.45 +0.12 (+0.81%) Q2 2026 earnings call transcript
Russell 1000 member Rebalance outlook locked
Going-concern doubt — flagged Jul 23, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Jul 23, 2026
Market Cap
$11.85B
Shares
797.75M
Volume · Oct 27 5.04M Avg daily vol (3M) 6.06M

Analyst Estimates

Compare analyst forecasts for Summit Therapeutics Inc. across metrics and forecast periods.

Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.

Compiled consensus

These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.

Captured 2026-10-27 13:17 UTC · Publication dates shown per estimate · 8 metric / period groups

FY ending 2026-12-31

Analyst estimates for FY ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
GBP
Publication date not stated
-1.22
-0.84
-0.50
11
-0.84
-0.86
-0.86
-0.86
4
6
2
2
Revenue
GBP
Publication date not stated
0.00
2.94M
11.27M
15
 — — — — — — — —

FY ending 2027-12-31

Analyst estimates for FY ending 2027-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
GBP
Publication date not stated
-1.22
-0.88
-0.44
10
-0.88
-0.89
-0.88
-0.89
4
6
2
2
Revenue
GBP
Publication date not stated
0.00
41.93M
131.52M
15
 — — — — — — — —

Q ending 2026-09-30

Analyst estimates for Q ending 2026-09-30
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
GBP
Publication date not stated
-0.32
-0.21
-0.11
12
-0.21
-0.22
-0.21
-0.22
5
7
1
1
Revenue
GBP
Publication date not stated
0.00
53,790.00
379,000.00
14
 — — — — — — — —

Q ending 2026-12-31

Analyst estimates for Q ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
GBP
Publication date not stated
-0.51
-0.26
-0.043
11
-0.26
-0.25
-0.25
-0.25
3
6
2
2
Revenue
GBP
Publication date not stated
0.00
2.99M
11.27M
14
 — — — — — — — —
Key facts CIK 1599298 CUSIP 86627T108 13F (30d) 48 filings 48 filers Visit website Investor relations